Greenhill Dustin A, Wissinger Kevin, Trionfo Arianna, Solarz Mark, Kozin Scott H, Zlotolow Dan A
Department of Orthopaedic Surgery & Sports Medicine, Temple University Hospital.
Temple University School of Medicine.
J Pediatr Orthop. 2018 Jan;38(1):32-37. doi: 10.1097/BPO.0000000000000735.
Few studies have investigated outcomes after adjunct botulinum toxin type A (BTX-A) injections into the shoulder internal rotator muscles during shoulder closed reduction and spica cast immobilization in children with brachial plexus birth palsy. The purpose of this study was to report success rates after treatment and identify pretreatment predictors of success.
Children with brachial plexus birth palsy who underwent closed glenohumeral joint reduction with BTX-A and casting were included. Minimum follow-up was 1 year. Included patients did not receive concomitant shoulder surgery nor undergo microsurgery within 8 months. Records were reviewed for severity of palsy, age, physical examination scores, passive external rotation (PER), and subsequent orthopaedic procedures (repeat injections, repeat reduction, shoulder tendon transfers, and humeral osteotomy). Treatment success was defined in 3 separate ways: no subsequent surgical reduction, no subsequent closed or surgical reduction, and no subsequent procedure plus adequate external rotation.
Forty-nine patients were included. Average age at time of treatment was 11.5 months. Average follow-up was 21.1 months (range, 1 to 9 y). Thirty-two patients (65%) required repeat reduction (closed or surgical). Only 16% of all patients obtained adequate active external rotation without any subsequent procedure. Increased PER (average 41±14 degrees, odds ratio=1.21, P=0.01) and Active Movement Scale external rotation (average 1.3, odds ratio=2.36, P=0.02) predicted optimal treatment success. Limited pretreatment PER (average -1±17 degrees) was associated with treatment failure. Using the optimal definition for success, all patients with pretreatment PER>30 degrees qualified as successes and all patients with PER<15 degrees were treatment failures.
Pretreatment PER>30 degrees can help identify which patients are most likely to experience successful outcomes after shoulder closed reduction with BTX-A and cast immobilization. However, a large proportion of these patients will still have mild shoulder subluxation or external rotation deficits warranting subsequent intervention.
Level IV-therapeutic.
在臂丛神经产瘫患儿的肩关节闭合复位及肩人字石膏固定期间,很少有研究调查在肩部内旋肌注射A型肉毒毒素(BTX-A)后的疗效。本研究的目的是报告治疗后的成功率,并确定治疗成功的预处理预测因素。
纳入接受BTX-A辅助下肩关节盂肱关节闭合复位及石膏固定的臂丛神经产瘫患儿。最小随访时间为1年。纳入的患者在8个月内未接受同期肩部手术,也未接受显微手术。回顾记录,了解麻痹严重程度、年龄、体格检查评分、被动外旋(PER)以及随后的骨科手术(重复注射、重复复位、肩部肌腱转移和肱骨截骨术)。治疗成功以3种不同方式定义:无需后续手术复位、无需后续闭合或手术复位、无需后续手术且外旋充分。
纳入49例患者。治疗时的平均年龄为11.5个月。平均随访时间为21.1个月(范围1至9年)。32例患者(65%)需要重复复位(闭合或手术)。所有患者中只有16%在无需任何后续手术的情况下获得了充分的主动外旋。PER增加(平均41±14度,优势比=1.21,P=0.01)和主动运动量表外旋(平均1.3,优势比=2.36,P=0.02)预测了最佳治疗成功。治疗前PER受限(平均-1±17度)与治疗失败相关。使用成功的最佳定义,所有治疗前PER>30度的患者均被判定为成功,而所有PER<15度的患者均为治疗失败。
治疗前PER>30度有助于确定哪些患者在接受BTX-A辅助下肩关节闭合复位及石膏固定后最有可能获得成功的治疗结果。然而,这些患者中的很大一部分仍将有轻度肩关节半脱位或外旋缺陷,需要后续干预。
四级治疗性。